US29089Q1058 - Common Stock
EMERGENT BIOSOLUTIONS INC
NYSE:EBS (3/28/2024, 8:06:16 PM)
After market: 2.55 +0.02 (+0.79%)2.53
-0.06 (-2.32%)
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,500 full-time employees. The company went IPO on 2006-11-15. Its segments include Products Segment and Services Segment. The Products Segment includes the government-medical countermeasures (MCM) business, which focuses on procurement of MCM products and procured product candidates by domestic and international government customers. The company sells MCM products and procures product candidates to domestic and international non-government organizations and to governments outside of the United States. The company also includes the commercial business, which focuses on sales of NARCAN (naloxone HCI) Nasal Spray and its travelers' vaccines. The Services Segment consists of contract development and manufacturing (CDMO) services, which includes development services (process and analytical development), drug substance manufacturing and drug product manufacturing (fill/finish).
EMERGENT BIOSOLUTIONS INC
400 Professional Dr, Suite 400
Gaithersburg MARYLAND 20879
P: 12406313200
CEO: Robert G. Kramer
Employees: 2500
Website: https://emergentbiosolutions.com/
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with...
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA)...
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
EBS earnings call for the period ending December 31, 2023.
Here you can normally see the latest stock twits on EBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: